5245582025-07-012025-09-305245582025-09-305245582025-03-315245582025-04-012025-09-305245582025-07-012025-09-30in-capmkt:OtherExpenses1Member5245582025-07-012025-09-30in-capmkt:OtherExpenses2Member5245582025-04-012025-09-30in-capmkt:OtherExpenses1Member5245582025-04-012025-09-30in-capmkt:OtherExpenses2Member5245582025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582025-07-012025-09-30RelatedPartyTransactionDomain15245582025-06-30RelatedPartyTransactionDomain15245582025-09-30RelatedPartyTransactionDomain15245582025-07-012025-09-30RelatedPartyTransactionDomain25245582025-06-30RelatedPartyTransactionDomain25245582025-09-30RelatedPartyTransactionDomain25245582025-07-012025-09-30RelatedPartyTransactionDomain35245582025-06-30RelatedPartyTransactionDomain35245582025-09-30RelatedPartyTransactionDomain35245582025-07-012025-09-30RelatedPartyTransactionDomain45245582025-06-30RelatedPartyTransactionDomain45245582025-09-30RelatedPartyTransactionDomain45245582025-07-012025-09-30RelatedPartyTransactionDomain55245582025-06-30RelatedPartyTransactionDomain55245582025-09-30RelatedPartyTransactionDomain55245582025-07-012025-09-30RelatedPartyTransactionDomain65245582025-06-30RelatedPartyTransactionDomain65245582025-09-30RelatedPartyTransactionDomain65245582025-07-012025-09-30RelatedPartyTransactionDomain75245582025-06-30RelatedPartyTransactionDomain75245582025-09-30RelatedPartyTransactionDomain75245582025-07-012025-09-30RelatedPartyTransactionDomain85245582025-06-30RelatedPartyTransactionDomain85245582025-09-30RelatedPartyTransactionDomain85245582025-07-012025-09-30RelatedPartyTransactionDomain95245582025-06-30RelatedPartyTransactionDomain95245582025-09-30RelatedPartyTransactionDomain95245582025-07-012025-09-30RelatedPartyTransactionDomain105245582025-06-30RelatedPartyTransactionDomain105245582025-09-30RelatedPartyTransactionDomain105245582025-07-012025-09-30RelatedPartyTransactionDomain115245582025-06-30RelatedPartyTransactionDomain115245582025-09-30RelatedPartyTransactionDomain115245582025-07-012025-09-30RelatedPartyTransactionDomain125245582025-06-30RelatedPartyTransactionDomain125245582025-09-30RelatedPartyTransactionDomain125245582025-07-012025-09-30RelatedPartyTransactionDomain135245582025-06-30RelatedPartyTransactionDomain135245582025-09-30RelatedPartyTransactionDomain135245582025-07-012025-09-30RelatedPartyTransactionDomain145245582025-06-30RelatedPartyTransactionDomain145245582025-09-30RelatedPartyTransactionDomain145245582025-07-012025-09-30RelatedPartyTransactionDomain155245582025-06-30RelatedPartyTransactionDomain155245582025-09-30RelatedPartyTransactionDomain155245582025-07-012025-09-30RelatedPartyTransactionDomain165245582025-06-30RelatedPartyTransactionDomain165245582025-09-30RelatedPartyTransactionDomain165245582025-07-012025-09-30RelatedPartyTransactionDomain175245582025-06-30RelatedPartyTransactionDomain175245582025-09-30RelatedPartyTransactionDomain175245582025-07-012025-09-30RelatedPartyTransactionDomain185245582025-06-30RelatedPartyTransactionDomain185245582025-09-30RelatedPartyTransactionDomain185245582025-07-012025-09-30RelatedPartyTransactionDomain195245582025-06-30RelatedPartyTransactionDomain195245582025-09-30RelatedPartyTransactionDomain195245582025-07-012025-09-30RelatedPartyTransactionDomain205245582025-06-30RelatedPartyTransactionDomain205245582025-09-30RelatedPartyTransactionDomain205245582025-07-012025-09-30RelatedPartyTransactionDomain215245582025-06-30RelatedPartyTransactionDomain215245582025-09-30RelatedPartyTransactionDomain215245582025-07-012025-09-30RelatedPartyTransactionDomain225245582025-06-30RelatedPartyTransactionDomain225245582025-09-30RelatedPartyTransactionDomain22iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010Neuland Laboratories LimitedMain BoardEquity2025-04-012026-03-312025-11-072025-10-24INRLakhsQuarterlySecond quarterSingle segmentManufacturing of Active Pharmaceuticals2025-11-0714:35:002025-11-0716:05:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-02-10https://www.neulandlabs.com/sites/neulandlabs/files/neuland-labs/Investors/corporate-governance/policies-and-documents/RelatedPartyTransactionPolicy25.pdffalsefalseNot Applicable2025-07-012025-09-30UnauditedStandalone514273100017987000516071800022764000000-44031000076678400053412000225392000988626000387030400012904140000129041400032512500070100032582600009645880000000964588000-29270009616610001290050001075.1875.180075.1875.181. The financial results for the quarter and half year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 07, 2025. The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2025. <BR> <BR> 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". <BR> <BR> 4. During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the Half year ended September 30, 2024: Rs. 2,062.56 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. <BR> <BR> 5. The EPS for quarters has not been annualised.2025-04-012025-09-30UnauditedStandalone807025800096546000816680400038912040000-91967500014756080009924500042726400017289640006702610000146419400001464194000368793000-62630003625300000110166400000001101664000-292700010987370001290050001085.8785.870085.8785.87Manufacturing Expenses459562000Other Expenses529064000Manufacturing Expenses853310000Other Expenses8756540007875623000139953500002794610000591640002942700000168710000011302400012989500003959000001268415400054789820001121524000440921400039588800015221000001094220006188258000096984800012637088000002532124200012900500015993680000161226850001612268500089224300000010110570001903300000649990007083600000026766590007096290001354420002844720000298016200088318300045729740001924447000244770000065218980000091985570002532124200099245000-1621413000-12318900000-2764880000-21119000-145721000033540900001095473000042726400003505000-5286000-785430000697530000518490000-44697000000140650000-1432292000319020000003988460000-366944000000000004384000165412800000053301000000000000000006417800001116938000-5219290000000000047740300023451600084430001539590009951400000-19029000-9079020000-9079020001303790000395888000Re-measurement gains/(losses) on defined benefit plans-3911000Equity instruments through other comprehensive income0-3911000Re-measurement gains/(losses) on defined benefit plans-3911000Equity instruments through other comprehensive income0-3911000-984000-98400000-2927000-2927000Neuland Laboratories Limited******Dr. Davuluri Rama Mohan Rao******Executive Chairman and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval55616000-555000000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Vice-Chairman & CEO and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval55616000-555000000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******Vice-Chairman & Managing Director and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval55616000-555000000Neuland Laboratories Limited******Dr. Nirmala Murthy******Non-Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved50000-25000000Neuland Laboratories Limited******Prasad Raghava Menon******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved370000-25000000Neuland Laboratories Limited******Dr Christopher M Cimarusti******Non-Executive Non-Independent DirectorAny other transactionSitting Fee, Commission & Professional FeesApproved1109000-25000000Neuland Laboratories Limited******Sugata Sircar******Non Executive Independent DirectorAny other transactionSitting Fee, Commission & Professional FeesApproved350000-25000000Neuland Laboratories Limited******Pallavi Bhakru******Non Executive Independent DirectorAny other transactionSitting Fee, Commission & Professional FeesApproved450000-25000000Neuland Laboratories Limited******Mr Homi Rustam Khusrokhan******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved450000-25000000Neuland Laboratories Limited******Mr. Ravi Shankar Gopinath******Non Executive Independent DirectorAny other transactionSitting FeeApproved10000000Neuland Laboratories Limited******Mr. Abhijit Majumdar******Chief Financial Officer and KMPRemunerationApproved10565000-2908000-1937000Neuland Laboratories Limited******Mrs. Sarada Bhamidipati******Company Secretary & Complinace OfficerRemunerationApproved2600000-345000-293000Neuland Laboratories Limited******Mrs. Davuluri Vijaya Rao******Relative of DirectorAny other transactionOffice Lease rentApproved475500000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Vice-Chairman & CEO and KMPAny other transactionOffice Lease rentApproved691600000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******Vice-Chairman & Managing Director and KMPAny other transactionOffice Lease rentApproved691600000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Vice-Chairman & CEO and KMPAny other transactionSecurity Deposit givenApproved01214000012140000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******Vice-Chairman & Managing Director and KMPAny other transactionSecurity Deposit givenApproved01214000012140000Neuland Laboratories Limited******Mrs. Davuluri Vijaya Rao******Relative of PromotersAny other transactionSecurity Deposit givenApproved019200001920000Neuland Laboratories Limited******Neuland Laboratories INC******Wholly owned subsidiaryAny other transactionBusiness PromotionApproved91023000-79499000-74899000Neuland Laboratories Limited******Neuland Laboratories KK******Wholly owned subsidiaryAny other transactionBusiness PromotionApproved16184000-7525000-7024000Neuland Laboratories Limited******Neuland Laboratories Limited Employees Group Gratuity Scheme******Post Employment Benefit TrustAny other transactionContribution to Employee Gratuity TrustApproved1800000000Neuland Laboratories Limited******Neuland Foundation******Entities with joint control or significant influence over entityAny other transactionContribution towards CSRApproved2425400000350940000